TRT monitoring schedule: which labs, when, and what triggers a dose change
A personalized testosterone protocol should include a full baseline panel before the first dose, a recheck of testosterone, hematocrit and symptoms 3 to 6 months after starting, and yearly monitoring after that. Under the Endocrine Society's 2018 guideline, a hematocrit above 54% means pausing therapy, then restarting at a lower dose once it comes down. A PSA rise of more than 1.4 ng/mL within the first 12 months, or a confirmed PSA above 4.0 ng/mL, calls for a urology referral.
Testosterone therapy is not a prescription you fill once and forget. It is a protocol that gets measured, adjusted and measured again. Here is the schedule the guideline lays out, the numbers that change a dose, and how BioCure Health runs it for patients in 47 states.
Before your first dose: the baseline panel
The Endocrine Society's testosterone therapy guideline (Bhasin et al., Journal of Clinical Endocrinology & Metabolism, 2018) recommends diagnosing low testosterone only when you have consistent symptoms and unequivocally low levels, confirmed by repeat morning, fasting measurements of total testosterone. The baseline panel does two jobs: it confirms the diagnosis, and it gives every future result something to be compared against.
| Test | Why it is on the baseline panel |
|---|---|
| Total testosterone (morning, fasting, repeated) | Confirms deficiency; a single low reading is not enough |
| Free testosterone and SHBG | Clarifies borderline results, since SHBG changes how much testosterone is actually available |
| LH and FSH | Separates primary (testicular) from secondary (pituitary or hypothalamic) causes, which changes the workup and treatment options |
| Hematocrit (CBC) | Testosterone raises red blood cell production, so you need a starting point |
| PSA | For men in the age and risk groups where prostate monitoring applies, after a discussion of benefits and risks |
| Estradiol | Not a core guideline requirement, but many clinicians record it so later symptoms can be interpreted |
| Lipid panel and A1c | Cardiometabolic baseline; low testosterone often travels with weight gain and insulin resistance |
| Blood pressure | The FDA now requires a blood pressure warning across testosterone products |
If your LH and FSH point to a secondary cause, the guideline calls for further evaluation, such as prolactin and iron studies, before treatment. Free versus total testosterone is one of the most misread parts of a panel; we cover it in this guide to free and total testosterone.
Fertility comes up at baseline, not later. The guideline recommends against starting testosterone in men who plan to have children in the near term, because external testosterone suppresses LH and FSH, the signals your testes need to make sperm. If fertility matters to you, say so at the first visit. Approaches that raise your own production exist, and they change the monitoring plan.
The guideline also lists situations where therapy should not start without further evaluation, including an elevated hematocrit, a palpable prostate nodule, an elevated PSA without urological evaluation, and untreated severe sleep apnea.
3 to 6 months: the first real checkpoint
This visit is where a protocol becomes personal. The guideline recommends checking testosterone 3 to 6 months after starting, with a target in the mid-normal range. For injectable testosterone cypionate or enanthate, the level is measured midway between injections. Some clinicians also check a trough level, drawn just before the next injection, to see whether levels fall too low by the end of the cycle; that is clinical practice rather than a guideline requirement.
At the same checkpoint, the guideline calls for:
- Hematocrit, rechecked at 3 to 6 months.
- A symptom review, at 3 to 12 months, to see whether energy, libido, mood or other target symptoms have actually responded, and whether side effects have appeared.
- PSA, at 3 to 12 months, for men enrolled in prostate monitoring.
Blood pressure belongs on the list too. The FDA's class-wide testosterone labeling changes added a warning about increased blood pressure, along with results from the TRAVERSE cardiovascular safety trial, to testosterone product labels.
| Finding at follow-up | What usually happens |
|---|---|
| Testosterone above the mid-normal target | Dose lowered or interval adjusted |
| Testosterone below target with persistent symptoms | Dose or frequency adjusted upward |
| Hematocrit above 54% | Therapy paused, cause evaluated, restarted at a reduced dose |
| PSA meets referral criteria | Urology referral before continuing as planned |
| Blood pressure rising | Blood pressure addressed and protocol reviewed |
| Levels on target but no symptom benefit | Diagnosis and the value of continuing are reassessed |
Notice that a number alone rarely drives the decision. Your clinician weighs the lab value, the timing of the draw, and how you feel. That interpretation is the reason a doctor should walk you through your results.
Hematocrit: the 54% line
Testosterone stimulates red blood cell production, and a rising hematocrit (erythrocytosis) is one of the most common reasons a protocol gets adjusted. Thicker blood is the concern.
The Endocrine Society guideline is specific: if hematocrit rises above 54%, stop therapy until hematocrit falls to a safe level, evaluate for hypoxia and sleep apnea, and then restart at a reduced dose. In practice, clinicians may also change the formulation or split the dose into smaller, more frequent injections, since injectable forms tend to raise hematocrit more than transdermal ones.
What this means for you: a hematocrit that creeps up is not a reason to panic, but it is a reason to recheck on schedule. A clinic that never draws a CBC after you start is not monitoring you.
PSA: when a rise means a urology referral
Testosterone can raise PSA modestly as prostate tissue responds, so some rise is expected. The guideline's criteria separate an expected change from one that needs a specialist.
Prostate monitoring under the guideline applies to men 55 to 69, and to men 40 to 69 at increased risk of prostate cancer (for example, Black men or men with a first-degree relative with prostate cancer), who choose monitoring after discussing benefits and risks. PSA is checked before starting, again at 3 to 12 months, and then according to standard prostate cancer screening guidance.
The guideline recommends urological consultation if any of these occur:
- PSA increases by more than 1.4 ng/mL within 12 months of starting testosterone
- A confirmed PSA above 4.0 ng/mL at any time
- A prostate abnormality found on digital rectal exam
- Substantial worsening of lower urinary tract symptoms
Yearly: the ongoing monitoring schedule
Once you are stable, the guideline moves to annual review: whether symptoms are still responding, whether side effects have appeared, and whether the labs support continuing at the current dose. Bone density is checked when indicated; the guideline suggests measuring it after 1 to 2 years of therapy in men with osteoporosis or a low-trauma fracture.
| Timepoint | Labs and checks | What the clinician is looking for |
|---|---|---|
| Baseline | Total T (repeated), free T, SHBG, LH, FSH, CBC/hematocrit, PSA when indicated, lipids, A1c, blood pressure | Confirm the diagnosis, find the cause, rule out reasons not to start |
| 3 to 6 months | Testosterone (mid-interval for injections), hematocrit, symptom review, blood pressure, PSA at 3 to 12 months when monitored | Is the dose right, and is it working safely? |
| Every 12 months | Testosterone, hematocrit, symptom review, blood pressure, PSA per screening guidance, lipids and A1c | Is the protocol still right for you? |
| 1 to 2 years, when indicated | Bone density (lumbar spine and/or hip) | Bone response in men with osteoporosis or fracture |
Any dose change restarts a shorter loop: adjust, recheck, review. If you want to read your own report, our guide to understanding bloodwork on TRT walks through each marker.
How BioCure schedules monitoring and reviews your results
When you compare telehealth testosterone clinics, judge them on monitoring, not marketing. Fair criteria: Does the clinic run a full baseline panel before prescribing? Does it put the 3 to 6 month and yearly labs on a written schedule? Will a clinician explain your results and the thresholds above? Does it offer an option for men who want to protect fertility? Can you get labs drawn conveniently?
Here is how BioCure handles each step:
- Intake and consult. A short online intake (about 5 minutes), then a video consultation with a physician. The consult is $199 and can be credited back with a membership.
- Baseline labs. Choose an at-home kit with an in-home phlebotomist visit, or in-lab testing. Our comprehensive male panel covers hormones, thyroid, lipids, metabolic and organ markers. Results arrive in 7 to 14 days.
- A 1:1 results review. Every result is interpreted with a specialist, who explains your numbers and builds your protocol.
- A protocol that fits your goals. bioOptimize is foundational. bioRestore uses medications that raise your body's own testosterone without direct hormone replacement, which is the route to discuss if fertility matters to you. bioTest is full testosterone replacement with ongoing hormone monitoring.
- Scheduled follow-up. Regular testing is built in, and each new set of labs gets the same 1:1 review before any dose change.
BioCure is physician-led, licensed to treat patients in 47 states (your state is confirmed at intake), with a physical clinic in the Fort Lauderdale area for patients who prefer in-person visits. It is a good fit if you want structured lab monitoring and direct access to clinicians. It does not bill insurance directly, so if you need TRT covered by your plan, an insurance-based provider may suit you better. Many BioCure patients pay with HSA or FSA funds using the invoices and documentation we provide.
Frequently asked questions
How often should I get blood work on TRT?
Under the Endocrine Society's 2018 guideline, labs are drawn at baseline, again 3 to 6 months after starting, and then once a year when you are stable. Any dose change usually triggers an extra recheck. Your clinician may test more often if hematocrit, PSA or blood pressure is moving.
What hematocrit is too high on testosterone?
The guideline uses 54% as the action line. Above it, therapy is paused until hematocrit returns to a safe level, you are evaluated for causes such as sleep apnea, and treatment restarts at a lower dose.
When should I check testosterone levels on cypionate injections?
The guideline recommends measuring testosterone midway between injections, about 3 to 6 months after starting, with a target in the mid-normal range. Some clinicians add a trough draw just before the next injection to see whether levels drop too low.
Does TRT raise PSA, and when is that a problem?
A modest PSA rise is common on testosterone. The guideline recommends a urology referral if PSA rises more than 1.4 ng/mL within the first 12 months, if a PSA above 4.0 ng/mL is confirmed, if a digital rectal exam finds an abnormality, or if urinary symptoms worsen substantially.
Can I do TRT monitoring through telehealth?
Yes, as long as the clinic arranges real lab draws and a clinician reviews them with you. BioCure offers at-home kits with an in-home phlebotomist or in-lab testing, results in 7 to 14 days, and a 1:1 review with a specialist before any change to your protocol.
Optimized testosterone is not a level you reach once. It is a level you keep confirming, with a schedule you understand and a clinician who explains every result.
Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838. Your future self will thank you.